BK0025 Animal Health II
- 629.080
- +13.579+2.21%
Hailey Biotech (603718.SH) reported 2023 results, net profit of 62.882 million yuan, a year-on-year decrease of 48.30%
Hailey Biotech (603718.SH) released its 2023 annual report, achieving revenue of 241 million yuan, a year-on-year decrease of 19.76%. Net profit attributable to shareholders of listed companies was 62.882 million yuan, a year-on-year decrease of 48.30%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 11.8219 million, a year-on-year decrease of 52.36%. It is proposed to distribute a cash dividend of 0.287 yuan (tax included) for every 10 shares to all shareholders.
Express News | Hailey Biotech: Net loss of 3.7194 million yuan in the first quarter
China Animal Husbandry Co., Ltd. (600195.SH)'s net profit for the first quarter of 76.53 million yuan decreased by 45.53% year-on-year
On April 29, Ge Longhui Co., Ltd. (600195.SH) announced that in the first quarter of 2024, the company's operating income was 1,125 billion yuan, up 5.97% year on year; net profit attributable to shareholders of listed companies was 76.53 million yuan, a year-on-year decrease of 45.53%; and basic earnings per share were 0.0749 yuan/share.
Express News | Biotech Co., Ltd.: The subsidiary obtained a new veterinary drug registration certificate
Keqian Biotech (688526.SH): Net profit of 87.228 million yuan in the first quarter decreased 35.64% year-on-year
On April 29, Ge Longhui Biotech (688526.SH) released its first quarter report. Operating revenue was 200 million yuan, down 26.68% year on year, net profit was 87.228 million yuan, down 35.64% year on year, after deducting non-net profit of 76.1578 million yuan, down 40.56% year on year, with basic earnings of 0.18 yuan per share.
Keqian Biology (688526) First Coverage Report: Product Strength+R&D Strength Building Core Competitiveness of Leading Companies Without Forced Exemption of Pig Seedlings
In the short term, as 24H2 pig prices enter an upward cycle, demand for animal insurance is expected to pick up. Pig prices have continued to be low since 23 years, and the downstream pig farming industry has been in losses for 15 consecutive months. The triple impact of financial pressure, pessimistic expectations, and the epidemic
Jinhe Biotech (002688.SZ): Net profit of 45.1432 million yuan in the first quarter increased 22.27% year-on-year
On April 28, Ge Longhui (002688.SZ) released its report for the first quarter of 2024, with operating income of 519 million yuan, down 1.49% year on year; net profit attributable to shareholders of listed companies was 45.1432 million yuan, up 22.27% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.872 million yuan, up 28.56% year on year; basic earnings per share were 0.0578 yuan.
China Post Securities released a research report on April 28 stating that Placo (603566.SH) was rated to increase its holdings. The main reasons for the rating include: 1) Comments: Pig seedlings are a drag and management efficiency is improved; 2) Produc
China Post Securities released a research report on April 28 stating that Placo (603566.SH) was rated to increase its holdings. The main reasons for the rating include: 1) Comments: Pig seedlings are a drag and management efficiency is improved; 2) Product reserves are abundant, waiting for pet vaccines and non-plague vaccines to be effective. (Mainichi Keizai Shimbun)
What You Need To Know About The Pulike Biological Engineering, Inc. (SHSE:603566) Analyst Downgrade Today
One thing we could say about the analysts on Pulike Biological Engineering, Inc. (SHSE:603566) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forec
Huisheng Biotech (300871): Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals
Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals. The company achieved operating income of 1,020 billion yuan in 2023, -0.31% year-on-year, mainly due to downstream aquaculture losses and financial constraints
China Animal Husbandry Co., Ltd. (600195) 2023 Report Review: Low industry demand is dragging down Dongbao's main business and is expected to return to a growth trajectory in 24 years
Matters: The company released its 2023 annual report: annual revenue of 5.406 billion yuan, -8.24% year on year, net profit to mother of 403 million yuan, year-on-year, -26.73% year-on-year, net profit of 279 million yuan after deduction, year-on-year
Reipu Biotech (300119): Continuing the growth trend, swine and pet vaccines are expected to release elasticity
1Q24 results are in line with our expectations, Ruipu Biotech announced 1Q24 results: the company achieved revenue of 533 million yuan, +20.4% year-on-year, net profit to mother was 88 million yuan, +8.3% year-on-year, deducted from non-return to mother
Bio Co., Ltd. (600201): Non-foot-and-mouth disease products reinforce product matrix profitability and steady recovery
The 2023 and 1Q24 results are in line with our expectations, Biotech Co., Ltd. announced the 2023 and 1Q24 results: the company achieved revenue of 1,598/348 million yuan in 2023/1Q24, +4 year-on-year respectively.
Placo (603566): The swine vaccine boom is under pressure and concerns about procyclical performance to release flexibility
Results for 2023 and 1Q24 fell short of our expectations Placo announced 2023 and 1Q24 results: the company achieved revenue of $12.5/235 million in 2023/1Q24, +1.84% YoY /-
Biotech Co., Ltd. (600201): Strong performance, strong performance, new products blossom, and the leader in animal insurance innovation continues to grow
The performance is resilient, and new products have blossomed more, and the leading animal insurance innovators continue to grow, maintaining the release of the 2023 annual report and the 2024 quarterly report by “buy” rating companies, with 2023 revenue of 1,598 billion yuan (+4.55%).
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gr
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gross margin of government harvesting increased significantly, and the growth rate of large individual pig seedlings was impressive; 3) continuous investment in research and development, and the world's first animal mRNA vaccine production workshop passed static inspection. (Mainichi Keizai Shimbun)
Shenlian Biotech (688098.SH): Net loss of 2.09 million yuan in the first quarter
Gelonghui, April 26 | Shenlian Biotech (688098.SH) released its first quarter report. Operating revenue was 880.58 million yuan, up 7.58% year on year, with a net loss of 2.209 million yuan, after deducting non-net loss of 2.889 million yuan, and basic earnings per share of -0.01 yuan.
Reipu Biotech (300119.SZ): In the future, it is planned to launch products such as oral insect repellents, cat fever monoclonal antibodies, canine quadruplets, etc.
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024, to discuss “What is the current channel development situation in the pet sector and the channel side plans for this year? What big products are worth looking forward to?” The company replied that the company has set up nearly 100 core dealers in all provinces and cities across the country, covering major Tier 1 and 2 cities across the country, and has covered more than 5,000 channel stores nationwide. In 2024, the company will continue to optimize dealers and sink channels to prefecture-level markets; form a mutually beneficial and win-win mechanism with core dealers, deepen cooperation and bonds; and strengthen
Ruipu Biotech (300119.SZ): This year, the company also plans to market a live recombinant H5 vaccine against duck fever, as well as several Chinese veterinary drugs such as bacteriophages and Xubiying extract
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “What major products will the company launch in the poultry sector in the past two years?” The company replied that in the poultry sector, the company focuses on multivalent multivalent vaccines, original pharmaceutical preparations, Chinese veterinary medicine products, etc. Recently, the company received three new veterinary drug certificates for the triple inactivated vaccine (LaSota strain+TJ-4 strain+RP-8-c strain), and Avian Adenovirus (H9 subtype), and aims to launch it on the market this year. In addition, the company also plans to go public and restructure Duck Fever this year
Reipu Biotech (300119.SZ): The cat triple vaccine was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter
Gelonghui April 26 | Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “The current promotion status of the triple vaccine for cats?” The company replied that the triple vaccine for cats was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter, and the terminals covered 4,600 pet hospitals. Up to now, there have been no cases of side effects of the triple vaccine for cats. The safety and efficacy have reached the expected level, and it has gradually developed a reputation among pet hospitals and pet owners. During the reporting period, “Rui Meow Shu” was the only officially designated vaccine for the FiFe China Cat Race. It was a professional cat racing cat